Navigation Links
Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
Date:12/22/2010

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi–arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, acceptance of the Company's NDA by the FDA, FDA's acceptance of the Company's request for and granting of priority review to the Company's NDA, approval of the Company's NDA by the FDA of the chemosaturation system for the treatment of metastatic melanoma, adoption, use and resulting sales, if any, of the chemosaturation system in the United States, the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, actions by the FDA or other regulatory agencies, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the co
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... YORK , Sept. 16, 2014 The ... Foundation (HNF) announced today an agreement to collaborate on ... and support the development of a stronger CMT patient ... financial support to several HNF,s initiatives including: ... in the HNF website featuring  HNF newsletters, materials and ...
(Date:9/15/2014)... , Sept. 16, 2014  Bayer HealthCare and ... Finland , have begun to ... ODM-201, an investigational oral androgen receptor inhibitor in ... in men with castration-resistant prostate cancer who have ... detectable metastases. The trial is designed to determine ...
(Date:9/15/2014)... , Sept. 15, 2014 /CNW/ - Health Minister Rona ... will make available for donation over $2.5 million in personal ... aid in the global response to the Ebola outbreak in ... WHO reported a shortage of equipment in the affected countries ... by front-line workers in the affected countries. ...
Breaking Medicine Technology:Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 2Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 3
... 28 Having hypertension, or high blood,pressure, reduces blood ... to a new study presented today at the annual ... "While hypertension is not a cause of Alzheimer,s disease, ... brain that increases its vulnerability,to the effects of the ...
... to ... total knee replacement, MINNEAPOLIS, ... of OrthoGlide Medial Knee Implant initial,clinical data., Data representing ... was presented on November 10th, 2007 at the,American College of ...
Cached Medicine Technology:High Blood Pressure May Heighten Effects of Alzheimer's Disease 2Clinical Data Presented on OrthoGlide(R) Medial Knee Implant 2
(Date:9/15/2014)... Club wear is provocative, revealing, or fetish ... with a very relaxed dress code. There are various types ... on the location of the club, the club's dress code ... and retailer, has delightedly pronounced its new series of delicate ... low prices. , A nightclub (also known as a discothèque, ...
(Date:9/15/2014)... 2014 1Heart Caregiver Services Training ... staff of Regency Park Oak Knoll during the ... Executive Director Gladys Broxton. This continuing professional education ... 1Heart Shirley Billedo and Regency Park officers of ... Jeanine Hernandez and Activities Coordinator Alfonso Escalante. , ...
(Date:9/15/2014)... BROOK, Ill. (PRWEB) September 15, 2014 ... at risk for stroke who might benefit from aggressive ... in the journal Radiology. , The study looked ... of the major blood vessels supplying blood to the ... stenosis is the primary cause of up to 20 ...
(Date:9/15/2014)... neuroscience researchers at the University of Copenhagen have ... cause Parkinson,s disease. The findings have recently been ... . , The defining symptoms of Parkinson,s ... There is currently no cure for the condition, ... with the potential to shed some light on ...
(Date:9/15/2014)... 15, 2014 Today, Zane Benefits, the ... Bank’s Speaking on Business radio show. , According ... so employers know it doesn’t make sense to choose ... also save the employer and employee as much as ... of Zions Bank's Speaking on Business , Chris ...
Breaking Medicine News(10 mins):Health News:Delicate Club Wears Are For Sale At Fecbek.com 2Health News:1Heart Caregiver Services Training Director Randolph Neil Conducted In-Service Training at Regency Park Oak Knoll Pasadena 2Health News:1Heart Caregiver Services Training Director Randolph Neil Conducted In-Service Training at Regency Park Oak Knoll Pasadena 3Health News:1Heart Caregiver Services Training Director Randolph Neil Conducted In-Service Training at Regency Park Oak Knoll Pasadena 4Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 2Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 3Health News:Researchers debunk myth about Parkinson's disease 2Health News:Zane Benefits Featured on Zions Bank Speaking on Business 2
... Oregon Health & Science University,s Vaccine and Gene Therapy Institute ... of infection before it becomes a rapidly replicating, ... the spread of the disease. The research is published in ... and will appear in a future printed edition. ...
... Bob Woodruff was injured while reporting in Iraq in 2006, ... his ability to recall and produce common words a ... language skills thanks to intensive behavioral therapy reading and ... for patients with aphasia has always been and will always ...
... Martek Biosciences Corporation (Nasdaq: MATK ) announced ... quarter of fiscal 2009 on March 4, 2009, at approximately ... 4:45 p.m. ET Martek will conduct a conference call to ... listen to the call live via webcast by visiting Martek,s ...
... but not available in U.S., was stopped early due ... -- A large study of tibolone, a drug used ... halted early after researchers found that the synthetic steroid ... survivors of the disease. , Tibolone isn,t available in ...
... Patient Check-In Company(TM), the leader in patient-intake, announced ... bringing total investment to date to $25 million. ... fund of the BlueCross BlueShield Association, and Sandbox ... Venture Partners, HLM Venture Partners, and Long River ...
... pathway that is responsible for generating excess connective tissue ... human patients with scleroderma. The study, published by Cell ... Developmental Cell , also reveals an intriguing but unexpected ... disease. , Platelet derived growth factors (PDGF) regulate ...
Cached Medicine News:Health News:OHSU vaccine research targets HIV in the slower, early stage of infection 2Health News:Exploring new pathways to language 2Health News:Menopause Drug Tied to Breast Cancer Recurrence 2Health News:Phreesia Secures $11.6M Series C Funding Led by BlueCross BlueShield Venture Partners and Sandbox Industries 2Health News:Phreesia Secures $11.6M Series C Funding Led by BlueCross BlueShield Venture Partners and Sandbox Industries 3Health News:Phreesia Secures $11.6M Series C Funding Led by BlueCross BlueShield Venture Partners and Sandbox Industries 4Health News:Tumor suppressor may attenuate fibrotic disease 2
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
Medicine Products: